Immunological Interaction Between the Host and Candida Albicans Biofilm

December 6, 2016 updated by: Universitaire Ziekenhuizen KU Leuven

Immunological and Molecular Interaction Between the Host and Candida Albicans Biofilm

Candida albicans is one of the most common nosocomial infection and the onset relies on the host immune status. The purpose of this study is to determine the immunological profile of patients infected with Candida albicans, that could ideally lead to a strategy to identify patients who could benefit from prophylaxis.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

237

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
    • Flemish Brabant
      • Leuven, Flemish Brabant, Belgium, 3000
        • Universitair Ziekenhuis Leuven

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with Candida albicans infection. Patients with no Candida albicans infection. Healthy volunteers

Description

Inclusion Criteria:

  • Patients infected with Candida albicans
  • Patients not infected with Candida albicans

Exclusion Criteria:

  • Underage patients
  • Non consenting patients
  • Unconscious patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Candida Infection
Patients infected with Candida albicans
No infection
Patients with no Candida albicans infection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Immunological phenotyping of patients
Time Frame: 2 months
2 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Mannose Binding Lectin levels
Time Frame: 1 month
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Universitaire Ziekenhuizen KU Leuven

Investigators

  • Study Director: Adrian Liston, Group Leader, Flemish Institute of Biotechnology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2013

Primary Completion (ACTUAL)

August 1, 2015

Study Completion (ACTUAL)

January 1, 2016

Study Registration Dates

First Submitted

June 19, 2013

First Submitted That Met QC Criteria

August 6, 2013

First Posted (ESTIMATE)

August 9, 2013

Study Record Updates

Last Update Posted (ESTIMATE)

December 7, 2016

Last Update Submitted That Met QC Criteria

December 6, 2016

Last Verified

December 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • S55012

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe